Pyxis Oncology (PYXS) Cash from Financing Activities (2020 - 2025)
Pyxis Oncology (PYXS) reported Cash from Financing Activities of $669000.0 for Q4 2025, up 1238.0% year-over-year from $50000.0 in Q4 2024, and up 8462.5% quarter-over-quarter from -$8000.0 in Q3 2025.
Pyxis Oncology (PYXS) Cash from Financing Activities (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 6 years of Cash from Financing Activities data on file, last reported at $669000.0 in Q4 2025.
- Cash from Financing Activities for Q4 2025 came in at $669000.0, up 1238.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.4 million (down 96.01% YoY), and the FY2025 annual result was $594000.0, down 99.0% from the prior year.
- Cash from Financing Activities grew to $669000.0 in Q4 2025 per PYXS's latest filing, from -$8000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $154.9 million in Q4 2021 and troughed at -$1.7 million in Q3 2021.
- A 5-year average of $24.3 million and a median of $50000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2021 and 2023: Cash from Financing Activities soared 15489900.0% in 2021, then tumbled 2950.0% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at $154.9 million in 2021, then plunged by 100.0% to $6000.0 in 2022, then tumbled by 516.67% to -$25000.0 in 2023, then soared by 300.0% to $50000.0 in 2024, then jumped by 1238.0% to $669000.0 in 2025.
- Business Quant data shows PYXS's Cash from Financing Activities at $669000.0 in Q4 2025, -$8000.0 in Q3 2025, and $50000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn | 669,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 669,000.00 |
| Dec 31, 2025 | 669,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Dec 31, 2024 | 50,000.00 |
| Dec 31, 2024 | 50,000.00 |
| Sep 30, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 110,000.00 |
| Jun 30, 2024 | 110,000.00 |
| Mar 31, 2024 | 57.51 Mn |
| Mar 31, 2024 | 57.51 Mn |
| Dec 31, 2023 | -25,000.00 |
| Dec 31, 2023 | -25,000.00 |
| Sep 30, 2023 | -171,000.00 |
| Sep 30, 2023 | -171,000.00 |
| Sep 30, 2022 | 6,000.00 |
| Sep 30, 2022 | 6,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Jun 30, 2022 | 1,000.00 |